Johnson & Johnson
(JNJ : NYQ)
Sector: Healthcare | Industry: Drug Manufacturers - General
$259.36
+5.57 (+2.19%)
MARKET CAP
$625.03B
FCF YIELD
N/A
CURRENT PRICE
$259.36
P/E RATIO
39.36x
MODEL INPUTS
Intrinsic Fair Value
$161.73
per share
5-YEAR FREE CASH FLOW PROJECTIONS
| Year | Projected FCF | Discount Factor (WACC) | Present Value (PV) |
|---|---|---|---|
| Base (0) | $19.31B | - | - |
| Year 1 | $21.24B | at 10.0% growth | $19.49B |
| Year 2 | $23.37B | at 10.0% growth | $19.67B |
| Year 3 | $25.71B | at 10.0% growth | $19.85B |
| Year 4 | $28.28B | at 10.0% growth | $20.03B |
| Year 5 | $31.10B | at 10.0% growth | $20.22B |
VALUATION ARITHMETIC
| Valuation Step | Value |
|---|---|
| PV of Projected FCFs (Sum Y1-Y5) | $99.26B |
| Terminal Value (Perpetuity at 2.5%) | $490.48B |
| PV of Terminal Value | $318.78B |
| Enterprise Value (EV) | $418.04B |
| Less: Total Debt | -$49.04B |
| Add: Total Cash & Equivalents | +$20.76B |
| Equity Value | $389.76B |
| Divided by: Shares Outstanding | 2,409,898,597.00 |
| Intrinsic Value (Fair Value per Share) | $161.73 |
FINANCIAL RATIOS & STATS
| Financial Metric | Value |
|---|---|
| Trailing P/E | 39.36x |
| Forward P/E | 22.32x |
| Price-to-Book (P/B) | 7.35x |
| Price-to-Sales (P/S) | 6.29x |
| Net Profit Margin (Net Income / Revenue) | 16.20% |
| Operating Profit Margin (EBIT / Revenue) | 25.06% |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Dividend Rate | $5.36 |
| Dividend Yield | 2.07% |
| Ex-Dividend Date | 2026-11-24 |
| Next Earnings Date | 2026-10-13 |